Pediatric B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy seen in children and adolescents and young adults (AYAs). This article highlights two recent studies that provide novel evidence of the association between obesity and increased risk of high-risk B-ALL and the effectiveness of a non-pharmacologic intervention for reducing minimal residual disease (MRD) risk.
An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.
In this issue of JAMA Oncology, two groups investigate the immune response to SARS-CoV-2, by proxy of antibody assays, in patients with solid malignant neoplasms who were undergoing active cancer therapy. With the concern that patients with cancer may not mount a robust protective immune response to SARS-CoV-2 infection or vaccination, the studies attempt to […]
Despite the pandemic interrupting trials and drug development in 2020, the US Food and Drug Administration (FDA) claims it is “full speed ahead” on the approval of novel cancer drug therapies. The authors of this Journal of the American Medical Association (JAMA) study wanted to verify these remarks, reviewing the FDA Hematology/Oncology Approvals website to […]
This new indication marks the second FDA approval for sacituzumab govitecan (Trodelvy, Immunomedics) and was based on the phase 2, single-arm TROPHY-U-01 main efficacy endpoints in objective response rate (ORR) and duration of response (DOR). With a relative 5-year survival rate of 5.5%, this is a significant advancement for patients with metastatic urothelial cancer (mUC), […]
The first biologic was approved in 1982, and since then, have become one of the fastest-growing segments of the US pharmaceutical market. Biologics are complex therapies used to treat a wide variety of conditions – conditions that are often untreatable by any other drug – and physicians should be up to speed on these four […]
According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, […]
In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health […]
Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.